Fairfax, VA, United States
Fairfax, VA, United States

Time filter

Source Type

Following a prostate cancer diagnosis, men are often faced with an array of treatment options, based on their prostate cancer severity or its potential to spread elsewhere within the body. Based on the tumor, treatment-related factors such as oncologic outcomes and side effects, as well as other patient-related considerations, these options can be overwhelming, which is why the guideline panel strongly suggests physicians and patients engage in shared decision making to select the best care option for each individual patient. "Selecting optimal care for each prostate cancer patient is a complex process that requires physicians to help patients choose options consistent with the patient's own values and in accordance with the best available scientific evidence," said Martin G. Sanda, MD, chair of the guideline development panel and chair of the department of urology at the Emory School of Medicine. "The new clinical guideline offers a framework to facilitate such shared decision-making, while also specifying which cancers are better managed by active surveillance, as well as providing guidance as to which treatments are appropriate for cancers warranting intervention.  It also provides specifics for implementing care options, managing side effects and administering post-treatment follow-up." The Localized Prostate Cancer Clinical Guideline makes 68 statements in total, including the recommendation that active surveillance is preferred for the care of low-risk localized prostate cancer, while radical prostatectomy or radiotherapy plus androgen deprivation therapy are recommended as the treatment standard for patients with intermediate- or high-risk localized prostate cancer. The guideline was developed by a panel of AUA, ASTRO and SUO-selected experts, all of whom have specific expertise with regard to prostate cancer. It was then distributed to peer reviewers of varying backgrounds as part of the AUA's extensive peer review process before being finally approved by the AUA, ASTRO and SUO Board of Directors. Shared decision making, care options based on cancer severity, as well as, specific care options including active surveillance, radical prostatectomy, high intensity focused ultrasound and focal therapy management are among the statements covered in this guideline.  The full text of the evidence-based Localized Prostate Cancer Guideline is now available online. NOTE TO REPORTERS: Experts are available to discuss this study. To arrange an interview with an expert, please contact the AUA Communications Office at 410-689-3932 or e-mail cfrey@AUAnet.org. About the American Urological Association: Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology, and has more than 21,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health policy. To learn more about the AUA, visit www.AUAnet.org. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/aua-astro-and-suo-release-new-clinical-guideline-on-standard-of-care-for-men-with-localized-prostate-cancer-300453577.html


News Article | May 10, 2017
Site: marketersmedia.com

— The Global Telescope Market Research Report 2017is a professional and in-depth study on the current state of the Telescope industry. In a word, This report studies Telescope in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer. Key companies included in this research are Celestron, Meade, Vixen Optics, Takahashi, ASTRO-PHYSICS, Bushnell, Bresser, ORION, Barska, Sky Watcher, Bosma, SharpStar, Visionking and TianLang. Market Segment by Region, this report splits Global into several key Region, with sales, revenue, market share and growth rate of Telescope in these regions, from 2011 to 2022 (forecast), like North America, Europe, China, Japan, Southeast Asia and India. Firstly, Telescope Market Split by product type, with production, revenue, price, market share and growth rate of each type, can be divided into Refracting telescope, Reflector Telescope and Catadioptric telescope. Split by application, this report focuses on consumption, market share and growth rate of Telescope in each application, can be divided into Enter-level, Intermediate Level, Advanced and Astronomical. 7 Global Telescope Manufacturers Profiles/Analysis 7.1 Celestron 7.1.1 Company Basic Information, Manufacturing Base and Its Competitors 7.1.2 Telescope Product Type, Application and Specification 7.1.2.1 Refracting telescope 7.1.2.2 Reflector Telescope 7.1.3 Celestron Telescope Production, Revenue, Price and Gross Margin (2015 and 2016) 7.1.4 Main Business/Business Overview 7.2 Meade 7.2.1 Company Basic Information, Manufacturing Base and Its Competitors 7.2.2 Telescope Product Type, Application and Specification 7.2.2.1 Refracting telescope 7.2.2.2 Reflector Telescope 7.2.3 Meade Telescope Production, Revenue, Price and Gross Margin (2015 and 2016) 7.2.4 Main Business/Business Overview 7.3 Vixen Optics 7.3.1 Company Basic Information, Manufacturing Base and Its Competitors 7.3.2 Telescope Product Type, Application and Specification 7.3.2.1 Refracting telescope 7.3.2.2 Reflector Telescope 7.3.3 Vixen Optics Telescope Production, Revenue, Price and Gross Margin (2015 and 2016) 7.3.4 Main Business/Business Overview Figure Picture of Telescope Figure Global Production Market Share of Telescope by Type in 2015 Figure Product Picture of Refracting telescope Table Major Manufacturers of Refracting telescope Figure Product Picture of Reflector Telescope Table Major Manufacturers of Reflector Telescope Figure Product Picture of Catadioptric telescope Table Major Manufacturers of Catadioptric telescope Table Telescope Consumption Market Share by Application in 2015 Figure Enter-level Examples Figure Intermediate Level Examples Figure Advanced Astronomical Examples Figure North America Telescope Revenue (Million USD) and Growth Rate (2011-2021) Figure Europe Telescope Revenue (Million USD) and Growth Rate (2011-2021) Figure China Telescope Revenue (Million USD) and Growth Rate (2011-2021) Figure Japan Telescope Revenue (Million USD) and Growth Rate (2011-2021) Figure Southeast Asia Telescope Revenue (Million USD) and Growth Rate (2011-2021) Figure India Telescope Revenue (Million USD) and Growth Rate (2011-2021) Figure Global Telescope Revenue (Million UDS) and Growth Rate (2011-2021) Table Global Telescope Capacity of Key Manufacturers (2015 and 2016) Table Global Telescope Capacity Market Share by Manufacturers (2015 and 2016) Figure Global Telescope Capacity of Key Manufacturers in 2015 Figure Global Telescope Capacity of Key Manufacturers in 2016 Table Global Telescope Production of Key Manufacturers (2015 and 2016) Table Global Telescope Production Share by Manufacturers (2015 and 2016) Figure 2015 Telescope Production Share by Manufacturers Figure 2016 Telescope Production Share by Manufacturers Table Global Telescope Revenue (Million USD) by Manufacturers (2015 and 2016) Table Global Telescope Revenue Share by Manufacturers (2015 and 2016) Table 2015 Global Telescope Revenue Share by Manufacturers Table 2016 Global Telescope Revenue Share by Manufacturers Table Global Market Telescope Average Price of Key Manufacturers (2015 and 2016) Figure Global Market Telescope Average Price of Key Manufacturers in 2015 Table Manufacturers Telescope Manufacturing Base Distribution and Sales Area For more information, please visit http://www.reportsweb.com/global-telescope-market-research-report-2017


News Article | May 11, 2017
Site: marketersmedia.com

This report studies Game Headset in Global Market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering Sennheiser SteelSeries Turtle Beach Cooler Master Creative Technology Mad Catz Hyperx (Kingston) Corsair Gioteck Logitech Razer Roccat Sades Sentey Skullcandy Kotion Electronic SADES Somic ASTRO Gaming Audio-Technica SOMIC By types, the market can be split into Wired Headsets Wireless Headsets By Application, the market can be split into Console PC By Regions, this report covers (we can add the regions/countries as you want) North America China Europe Southeast Asia Japan India Global Game Headset Market Professional Survey Report 2017 1 Industry Overview of Game Headset 1.1 Definition and Specifications of Game Headset 1.1.1 Definition of Game Headset 1.1.2 Specifications of Game Headset 1.2 Classification of Game Headset 1.2.1 Wired Headsets 1.2.2 Wireless Headsets 1.3 Applications of Game Headset 1.3.1 Console 1.3.2 PC 1.3.3 Application 3 1.4 Market Segment by Regions 1.4.1 North America 1.4.2 China 1.4.3 Europe 1.4.4 Southeast Asia 1.4.5 Japan 1.4.6 India 2 Manufacturing Cost Structure Analysis of Game Headset 2.1 Raw Material and Suppliers 2.2 Manufacturing Cost Structure Analysis of Game Headset 2.3 Manufacturing Process Analysis of Game Headset 2.4 Industry Chain Structure of Game Headset 8 Major Manufacturers Analysis of Game Headset 8.1 Sennheiser 8.1.1 Company Profile 8.1.2 Product Picture and Specifications 8.1.2.1 Product A 8.1.2.2 Product B 8.1.3 Sennheiser 2016 Game Headset Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.1.4 Sennheiser 2016 Game Headset Business Region Distribution Analysis 8.2 SteelSeries 8.2.1 Company Profile 8.2.2 Product Picture and Specifications 8.2.2.1 Product A 8.2.2.2 Product B 8.2.3 SteelSeries 2016 Game Headset Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.2.4 SteelSeries 2016 Game Headset Business Region Distribution Analysis 8.3 Turtle Beach 8.3.1 Company Profile 8.3.2 Product Picture and Specifications 8.3.2.1 Product A 8.3.2.2 Product B 8.3.3 Turtle Beach 2016 Game Headset Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.3.4 Turtle Beach 2016 Game Headset Business Region Distribution Analysis 8.4 Cooler Master 8.4.1 Company Profile 8.4.2 Product Picture and Specifications 8.4.2.1 Product A 8.4.2.2 Product B 8.4.3 Cooler Master 2016 Game Headset Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.4.4 Cooler Master 2016 Game Headset Business Region Distribution Analysis 8.5 Creative Technology 8.5.1 Company Profile 8.5.2 Product Picture and Specifications 8.5.2.1 Product A 8.5.2.2 Product B 8.5.3 Creative Technology 2016 Game Headset Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.5.4 Creative Technology 2016 Game Headset Business Region Distribution Analysis 8.6 Mad Catz 8.6.1 Company Profile 8.6.2 Product Picture and Specifications 8.6.2.1 Product A 8.6.2.2 Product B 8.6.3 Mad Catz 2016 Game Headset Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.6.4 Mad Catz 2016 Game Headset Business Region Distribution Analysis 8.7 Hyperx (Kingston) 8.7.1 Company Profile 8.7.2 Product Picture and Specifications 8.7.2.1 Product A 8.7.2.2 Product B 8.7.3 Hyperx (Kingston) 2016 Game Headset Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.7.4 Hyperx (Kingston) 2016 Game Headset Business Region Distribution Analysis 8.8 Corsair 8.8.1 Company Profile 8.8.2 Product Picture and Specifications 8.8.2.1 Product A 8.8.2.2 Product B 8.8.3 Corsair 2016 Game Headset Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.8.4 Corsair 2016 Game Headset Business Region Distribution Analysis 8.9 Gioteck 8.9.1 Company Profile 8.9.2 Product Picture and Specifications 8.9.2.1 Product A 8.9.2.2 Product B 8.9.3 Gioteck 2016 Game Headset Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.9.4 Gioteck 2016 Game Headset Business Region Distribution Analysis 8.10 Logitech 8.10.1 Company Profile 8.10.2 Product Picture and Specifications 8.10.2.1 Product A 8.10.2.2 Product B 8.10.3 Logitech 2016 Game Headset Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.10.4 Logitech 2016 Game Headset Business Region Distribution Analysis 8.11 Razer 8.12 Roccat 8.13 Sades 8.14 Sentey 8.15 Skullcandy 8.16 Kotion Electronic 8.17 SADES 8.18 Somic 8.19 ASTRO Gaming 8.20 Audio-Technica 8.21 SOMIC For more information, please visit http://www.wiseguyreports.com


News Article | May 18, 2017
Site: www.prnewswire.com

At the same time as the scientific and educational program, more than 200 exhibitors will demonstrate cutting-edge technology and medical device innovations for radiation oncology. New this year, daily science highlight sessions will spotlight the highest-rated studies grouped by cancer type (e.g., breast cancer, lung cancer). What, When and Where: American Society for Radiation Oncology (ASTRO) 59th Annual Meeting; Sunday, September 24 through Wednesday, September 27, 2017; San Diego Convention Center Press Registration: Credentialed journalists from accredited news organizations are invited to attend and report on the 2017 ASTRO Annual Meeting. Reporters registered by September 15, 2017, will receive the embargoed press kit prior to the meeting. More information for reporters and the press registration form are available online. News Briefings: News briefings on Sunday, Monday and Tuesday will highlight top-rated abstracts selected from the general program. Briefings will be available live on-site in San Diego and via webcast for registered press, with audio recordings and presenter slides posted online after each briefing. The final press program will be announced in early September. On-site Press Office: ASTRO will host an on-site press office in room 24B of the San Diego Convention Center with refreshments, access to Wi-Fi, power and a printer. ASTRO experts will be available for on-site and remote interviews. More Information: More information is available at the ASTRO Annual Meeting webpage. ABOUT ASTRO ASTRO is the premier radiation oncology society in the world, with more than 10,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals who specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, the Society is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, advancement of science and research, and advocacy. ASTRO publishes three medical journals, International Journal of Radiation Oncology • Biology • Physics (www.redjournal.org), Practical Radiation Oncology (www.practicalradonc.org) and Advances in Radiation Oncology (www.advancesradonc.org); developed and maintains an extensive patient website, RT Answers (www.rtanswers.org); and created the Radiation Oncology Institute (www.roinstitute.org), a nonprofit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment. To learn more about ASTRO, visit www.astro.org. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/astros-59th-annual-meeting-will-explore-the-art-and-science-of-radiation-oncology-300460061.html


News Article | May 18, 2017
Site: www.eurekalert.org

Press registration now open for San Diego meeting this September that will highlight more than 2,800 abstracts featuring advances in cancer research and clinical care ARLINGTON, Va., May 18, 2017 - Registration opens today for the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO), which will highlight advances in cancer research and clinical care involving radiation therapy, also known as radiotherapy. The meeting, which will be held September 24-27 at the San Diego Convention Center, is expected to attract more than 11,000 attendees from across the globe, including oncologists from all disciplines and members of the entire radiation oncology team. Online registration is available for media professionals. More than 2,800 abstracts sharing results from clinical trials and other research studies will be presented in conjunction with educational sessions and keynote addresses that underscore the meeting's theme, "The Healing Art and Science of Radiation Oncology." Keynote speakers include: At the same time as the scientific and educational program, more than 200 exhibitors will demonstrate cutting-edge technology and medical device innovations for radiation oncology. New this year, daily science highlight sessions will spotlight the highest-rated studies grouped by cancer type (e.g., breast cancer, lung cancer). What, When and Where: American Society for Radiation Oncology (ASTRO) 59th Annual Meeting; Sunday, September 24 through Wednesday, September 27, 2017; San Diego Convention Center. Press Registration: Credentialed journalists from accredited news organizations are invited to attend and report on the 2017 ASTRO Annual Meeting. Reporters registered by September 15, 2017, will receive the embargoed press kit prior to the meeting. More information for reporters and the press registration form are available online. News Briefings: News briefings on Sunday, Monday and Tuesday will highlight top-rated abstracts selected from the general program. Briefings will be available live on-site in San Diego and via webcast for registered press, with audio recordings and presenter slides posted online after each briefing. The final press program will be announced in early September. On-site Press Office: ASTRO will host an on-site press office in room 24B of the San Diego Convention Center with refreshments, access to Wi-Fi, power and a printer. ASTRO experts will be available for on-site and remote interviews. More Information: More information is available at the ASTRO Annual Meeting webpage. ASTRO is the premier radiation oncology society in the world, with more than 11,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals that specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, the Society is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, advancement of science and research, and advocacy. ASTRO publishes three medical journals, International Journal of Radiation Oncology * Biology * Physics and Practical Radiation Oncology and Advances in Radiation Oncology; developed and maintains an extensive patient website, http://www. ; and created the Radiation Oncology Institute, a non-profit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment. To learn more about ASTRO, visit http://www. .


News Article | May 15, 2017
Site: marketersmedia.com

— The “Public Safety LTE & Mobile Broadband Market: 2016 – 2030 – Opportunities, Challenges, Strategies & Forecasts” report presents an in-depth assessment of the global public safety LTE market, besides touching upon the wider LMR and mobile broadband industries. In addition to covering the business case, challenges, technology, spectrum allocation, industry roadmap, value chain, deployment case studies, vendor products, strategies, standardization initiatives and applications ecosystem for public safety LTE, the report also presents comprehensive forecasts for mobile broadband, LMR and public safety LTE subscriptions from 2016 till 2030. Browse 11 Chapters, 504 companies and 153 table and figures spread across 529 pages report @ http://www.reportsnreports.com/contacts/discount.aspx?name=560702. Also covered are public safety LTE service revenues, over both private and commercial networks. In addition, the report presents revenue forecasts for public safety LTE infrastructure, devices, integration services and management solutions. Latest research estimates that annual investments on public safety LTE infrastructure will reach $600 Million by the end of 2016. The market, which includes base stations (eNBs), mobile core and transport networking gear, is further expected to grow at a CAGR of 33% over the next four years. By 2020, these infrastructure investments will be complemented by over 4.4 Million LTE device shipments, including smartphones, rugged handheld terminals and vehicular routers. Due to the bandwidth limitations of their traditional voice-centric LMR (Land Mobile Radio) networks, public safety agencies are keen to leverage commercial cellular network technology to support their growing broadband application needs. Considering its thriving ecosystem, spectrum flexibility and performance metrics, LTE has emerged as the leading candidate for public safety mobile broadband networks. In addition, with the recent approval of the MCPTT (Mission Critical Push to Talk) voice standard as part of 3GPP Release 13, LTE has also become an attractive substitute for providing LMR-like voice services. The following companies and organizations have been reviewed, discussed or mentioned in the report: 3GPP (Third Generation Partnership Project), Aaeon, Abu Dhabi Police, Accelleran, AceAxis, ACMA (Australian Communications and Media Authority), Aculab, Adax, ADCOM911 (Adams County Communication Center), ADRF (Advanced RF Technologies), Advantech, Advantech Wireless, Aeroflex, Affarii Technologies, Affirmed Networks, Agile Networks, Airbus Defence and Space, Airbus Group, Air-Lynx, Airspan Networks, Airvana, Airwave Solutions, Ajman Police, Alcatel-Lucent, Altiostar Networks, Amdocs, Anite, Anritsu Corporation, APCO International (Association of Public-Safety Communications Officials), Apple, ARASKOM, Arcadyan, Argela, Aricent, ARItel, Arqiva, Artemis Networks, Aselsan, ASOCS, ASTRI (Hong Kong Applied Science and Technology Research Institute), ASTRID, ASTRO Solutions, Asus (ASUSTeK Computer), AT&T, Athena Wireless Communications, Athonet, ATIS (Alliance for Telecommunications Industry Solutions), Atlas Telecom, Avanti Communications Group Topics Covered: • Business case for public safety LTE and mobile broadband services, including key benefits and challenges • Technology, economics, trends, commercial commitments and deployment case studies • List of public safety LTE engagements worldwide • Public safety LTE infrastructure, devices and applications • Industry roadmap, value chain and standardization initiatives • Spectrum allocation, deployment models and funding strategies • Profiles and strategies of over 260 ecosystem players including public safety system integrators and LTE infrastructure/device OEMs • TCO analysis of private and commercial public safety LTE deployments • Military and tactical LTE deployments • Public safety LTE base station (eNB) form factor analysis • Exclusive interview transcripts from 5 key ecosystem players: Ericsson, Airbus Defence and Space, Sepura, Aricent and Parallel Wireless • Strategic recommendations for vendors, system integrators, public safety agencies and mobile operators • Public Safety LTE & Mobile Broadband Market analysis and forecasts from 2016 till 2030 ReportsnReports.com is single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. For more information, please visit http://www.reportsnreports.com/reports/560702-the-public-safety-lte-mobile-broadband-market-2016-2030-opportunities-challenges-strategies-forecasts.html?utm_source=MMgiti


The NIH and NCI cuts would be achieved largely by capping overhead costs associated with federal research funding at 10 percent, in contrast to the average 50 to 60 percent that institutions currently receive to defray the administrative costs of scientific research. Implementing an unrealistic cap on these administrative dollars would result in fewer jobs for researchers, especially for early career scientists, and less support for clinical trials. More dangerously, it could cause entire research programs to shut down. In addition to curtailing support for cancer research, the budget also proposes more than $600 billion in cuts to Medicaid that would limit patient access to health coverage and care. Multiple studies have demonstrated a link between inadequate health insurance and delayed cancer diagnosis and treatment, ultimately resulting in higher mortality rates. New limits on coverage for cancer patients will restrict their access to the treatments they need and deserve. Inadequate coverage also leads to higher costs that are felt throughout the economy. In March, ASTRO joined cancer research advocates in opposing these cuts in the President's draft budget proposal. Now that these proposed cuts have come to fruition in the official budget request, ASTRO strongly encourages Congress to support cancer patients nationwide by rejecting the cuts and pursuing alternatives that preserve the viability of cancer research and care. ABOUT ASTRO ASTRO is the premier radiation oncology society in the world, with more than 10,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals who specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, the Society is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, advancement of science and research, and advocacy. ASTRO publishes three medical journals, International Journal of Radiation Oncology • Biology • Physics (www.redjournal.org), Practical Radiation Oncology (www.practicalradonc.org) and Advances in Radiation Oncology (www.advancesradonc.org); developed and maintains an extensive patient website, RT Answers (www.rtanswers.org); and created the Radiation Oncology Institute (www.roinstitute.org), a nonprofit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment. To learn more about ASTRO, visit www.astro.org. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/presidents-budget-would-dramatically-undermine-progress-in-cancer-research-and-care-300463105.html


News Article | March 8, 2017
Site: globenewswire.com

NASHUA, N.H., March 08, 2017 (GLOBE NEWSWIRE) -- iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today reported financial results for the three and twelve months ended December 31, 2016. “Our fourth quarter revenue grew 15% sequentially compared to the third quarter of 2016, reflecting improved performance in our cancer therapy business,” said Ken Ferry, Chief Executive Officer.  “This included a stronger quarter for IORT system and balloon applicator sales, as result of greater sales activity, and increased procedure volume in both the U.S. and international markets.  We also had our strongest quarter of the year adding new customers in our skin electronic brachytherapy business.  Our cancer detection team continues to make good progress with the development of software tools that enhance the workflow and interpretation of 3D tomosynthesis breast exams.  We expect these tools to be a major growth opportunity for the Company over time.  Currently, these products are available in certain international markets and are pending FDA clearance in the United States.” Mr. Ferry added, “We remain confident in the longer term outlook for our business.  In the fourth quarter we made additional key investments in support of our goal of obtaining a CPT 1 reimbursement code for skin electronic brachytherapy, added sales personnel to support future growth in the skin therapy and cancer detection software markets, and had a robust presence at the two most important medical meetings that we attend, ASTRO and RSNA.  Also, in January 2017, we strengthened our balance sheet with the sale of our MRI CAD business for $3.2 million.” Revenue:  Total revenue for the fourth quarter of 2016 decreased 9% to $6.9 million from $7.6 million in the fourth quarter of 2015, reflecting a 15% increase in product revenue and a 21% decrease in service revenue.  The decrease in the Company’s revenue in the fourth quarter of 2016 was primarily driven by the comparable decline of therapy service revenue associated with the treatment of non-melanoma skin cancer in the United States.  On a sequential quarter basis, total revenue for the fourth quarter of 2016 increased 15% from $6.0 million in the third quarter of 2016.  Service revenue for the fourth quarter of 2016 was approximately 57% of total revenues compared to approximately 65% of total revenues in the fourth quarter of 2015. Cancer detection revenue for the fourth quarter of 2016 decreased by 3%, which includes digital mammography, breast density, MRI and CT CAD platforms, as well as the associated service revenue.  Therapy revenue decreased by 17%, which includes Xoft® Axxent® Electronic Brachytherapy System® product sales, as well as the associated service revenue. Gross Profit:  Gross profit for the fourth quarter of 2016 decreased to $4.5 million, or 65% of revenue, from $5.3 million, or 70% of revenue, for the fourth quarter of 2015. Operating Expenses:  Total operating expenses for the fourth quarter of 2016 increased to $7.8 million from $7.6 million for the fourth quarter of 2015. The year-over-year increase reflects investments in strategic growth drivers, partially offset by the Company’s cost reduction initiatives which were implemented in 2015. GAAP Net Loss:  Net loss for the fourth quarter of 2016 was $(3.3) million, or $(0.20) per share, compared with net loss of $(2.4) million, or $(0.15) per share, for the fourth quarter of 2015. Non-GAAP Adjusted EBITDA:  Non-GAAP adjusted EBITDA, a non-GAAP financial measure as defined below, was a loss $(2.0) million for the fourth quarter of 2016, compared with non-GAAP adjusted EBITDA loss of $(1.1) million for the fourth quarter of 2015. Non-GAAP Adjusted Net Income/Loss: Non-GAAP adjusted net loss, as defined below, for the fourth quarter of 2016 was $(3.2) million, or $(0.20) per share, compared with a non-GAAP adjusted net loss of $(2.2) million, or $(0.14) per share, for the fourth quarter of 2015. Cash and Cash Equivalents:  As of December 31, 2016, the Company had cash and cash equivalents of $8.6 million, compared with $15.3 million as of December 31, 2015. The Company used $1.6 million of cash from operating activities in the fourth quarter of 2016. Revenue:  Total revenue for fiscal year 2016 decreased 37% to $26.3 million from $41.6 million for fiscal year 2015, reflecting a 26% decrease in product revenue and a 42% decrease in service revenue. The decrease in the Company’s revenue in fiscal year 2016 was primarily driven by declining revenues related to the treatment of non-melanoma skin cancer in the United States. The decrease was also driven by a reduction of approximately $2.1 million of MRI-CAD product sales due to the Company’s exclusive distribution partner exercising its right in August 2015 to a fully paid-up license to distribute the software. This provided the Company with a cash payment of $2.0 million during the third quarter of 2015 that is being amortized over the term of the contract through July 2017.  Service revenue for fiscal year 2016 was approximately 60% of total revenues compared to approximately 66% of total revenues for fiscal year 2015. Cancer detection revenue for fiscal year 2016 decreased by 11%, which includes digital mammography, breast density, MRI and CT CAD platforms, as well as the associated service revenue.  When adjusted for the $2.1 million reduction in MRI-CAD product revenue, cancer detection revenues were essentially flat compared to fiscal year 2015.  Therapy revenue for fiscal year 2016 decreased by 59%, which includes Xoft® Axxent® Electronic Brachytherapy System® product sales, as well as the associated service revenue. Gross Profit:  Gross profit for fiscal year 2016 decreased to $18.5 million, or 70% of revenue, from $29.4 million, or 71% of revenue, for fiscal year 2015.  Gross profit for fiscal year 2016 included a U.S. medical device excise tax refund of $0.5 million. Operating Expenses:  Total operating expenses for fiscal year 2016 decreased to $28.5 million from $59.4 million for fiscal year 2015, which included $27.4 million of goodwill and long-lived asset impairment. Operating expenses for fiscal year 2015 were $32.0 million excluding the impairment.  The year-over-year decline reflects the effect of the Company’s cost reduction initiatives implemented in 2015. GAAP Net Loss:  Net loss for fiscal year 2016 was $(10.1) million, or $(0.63) per share, compared with net loss of $(32.5) million, or $(2.07) per share, for fiscal year 2015. Non-GAAP Adjusted EBITDA:  Non-GAAP adjusted EBITDA, a non-GAAP financial measure as defined below, was a loss of $(5.3) million for fiscal year 2016, compared with non-GAAP adjusted EBITDA of $3.9 million, or 9% of revenue, for fiscal year 2015. Non-GAAP Adjusted Net Income/Loss:  Non-GAAP adjusted net loss, as defined below, for fiscal year 2016 was $(9.8) million, or $(0.63) per share, compared with a non-GAAP adjusted net loss of $(2.2) million, or $(0.14) per share, for fiscal year 2015. iCAD management will host a conference call today at 4:30 p.m. Eastern Time to discuss the financial results and provide a company update.  The dial-in numbers are (855) 217-4501 for domestic callers and (716) 220-9431 for international callers.  The conference ID is 57732542.  A live webcast of the conference call will be available online at www.icadmed.com. A replay of the webcast will remain on the Company’s website until the Company releases its first quarter 2017 financial results.  In addition, a telephonic replay of the conference call will be available until March 15, 2017.  The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers.  The replay conference ID is 57732542. Use of Non-GAAP Financial Measures In its quarterly news releases, conference calls, slide presentations or webcasts, the Company may use or discuss non-GAAP financial measures as defined by SEC Regulation G.  The GAAP financial measures most directly comparable to each non-GAAP financial measure used or discussed, and a reconciliation of the differences between each non-GAAP financial measure and the comparable GAAP financial measure, are included in this press release after the condensed consolidated financial statements.  When analyzing the Company's operating performance, investors should not consider these non-GAAP measures as a substitute for the comparable financial measures prepared in accordance with GAAP.  The Company's quarterly news releases containing such non-GAAP reconciliations can be found on the Investors section of the Company's website at www.icadmed.com. iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while improving patient outcomes.  iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers.  iCAD’s Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is a painless, non-invasive technology that delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue.  The Xoft System is FDA cleared and CE marked for use anywhere in the body, including treatment of non-melanoma skin cancer, early-stage breast cancer and gynecological cancers.  The comprehensive iCAD technology platforms include advanced hardware and software, as well as management services designed to support cancer detection and radiation therapy treatments.  For more information, visit www.icadmed.com or www.xoftinc.com. "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995 Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.  Such factors include, but are not limited to the Company’s ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission.  The words “believe”, “demonstrate”, “intend”, “expect”, “would”, “could”, “consider”, “project”, “estimate”, “will”, “continue”, “anticipate”, “likely”, “seek”, and similar expressions identify forward-looking statements.  Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made.  The Company is under no obligation to provide any updates to any information contained in this release.  For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, including the 10-K for the year ended December 31, 2015, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov. RECONCILIATION OF NON-GAAP FINANCIAL MEASURES TO COMPARABLE GAAP MEASURES (Unaudited, in thousands, except per share amounts) The following is a reconciliation of the non-GAAP financial measures used by the Company to describe the Company's financial results determined in accordance with United States generally accepted accounting principles (GAAP).  An explanation of these measures is also included below under the heading "Explanation of Non-GAAP Financial Measures." While management believes that these non-GAAP financial measures provide useful supplemental information to investors regarding the underlying performance of the Company's business operations, investors are reminded to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP.  In addition, it should be noted that these non-GAAP financial measures may be different from non-GAAP financial measures used by other companies, and management may utilize other measures to illustrate performance in the future.  Non-GAAP financial measures have limitations in that they do not reflect all of the amounts associated with the Company's results of operations as determined in accordance with GAAP. The Company reports its financial results in accordance with United States generally accepted accounting principles, or GAAP.  However, management believes that in order to properly understand the Company's short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash or non-recurring items, when used as a supplement to financial performance measures in accordance with GAAP.  These items result from facts and circumstances that vary in frequency and/or impact on continuing operations.  Management also uses results of operations before such items to evaluate the operating performance of the Company and compare it against past periods, make operating decisions, and serve as a basis for strategic planning.  These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in the Company's ongoing business by eliminating certain non-cash expenses and other items that management believes might otherwise make comparisons of the Company's ongoing business with prior periods more difficult, obscure trends in ongoing operations or reduce management's ability to make useful forecasts.  Management believes that these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance.  In addition, management understands that some investors and financial analysts find this information helpful in analyzing the Company's financial and operational performance and comparing this performance to its peers and competitors. Management defines "Non-GAAP Adjusted EBITDA" as the sum of GAAP net income (loss) before provision for taxes, acquisition-related expenses, total other (income) expense, stock-based compensation expense, depreciation and amortization, severance, gain on sale, loss on warrant, loss on extinguishment of debt, amortization of acquired intangibles, patent litigation and recall costs, contingent consideration, indemnification, asset and goodwill impairment charges.  Management considers this non-GAAP financial measure to be an important indicator of the Company's operational strength and performance of its business and a good measure of its historical operating trends, in particular the extent to which ongoing operations impact the Company's overall financial performance. Management defines "Non-GAAP Adjusted Net Income (loss)" as the sum of GAAP net income (loss) before provision for the gain on sale of asset, severance, transaction, patent litigation and recall costs, contingent consideration, indemnification, loss on extinguishment of debt and asset and goodwill impairment charges. Management considers this non-GAAP financial measure to be an important indicator of the Company's operational strength and performance of its business and a good measure of its historical operating trends, in particular the extent to which ongoing operations impact the Company's overall financial performance. Management excludes each of the items identified below from the applicable non-GAAP financial measure referenced above for the reasons set forth with respect to that excluded item: On occasion in the future, there may be other items, such as significant asset impairments, restructuring charges or significant gains or losses from contingencies that the Company may exclude if it believes that doing so is consistent with the goal of providing useful information to investors and management.


PHOENIX--(BUSINESS WIRE)--Arizona Oncology, one of the largest medical groups in Arizona and a practice in The US Oncology Network, has demonstrated compliance with the standards of the American Society for Radiation Oncology (ASTRO) Accreditation Program for Excellence (APEx®), effective May 1, 2017 for a four-year accreditation of its radiation oncology services. APEx is an independent radiation oncology practice accreditation program developed by ASTRO based on a comprehensive set of sixteen evidence-based standards of radiation oncology practice. The sixteen standards are focused on five pillars of patient care: “Arizona Oncology is pleased to receive APEx accreditation at our Arizona Oncology Radiation Treatment Centers in Phoenix from the premier radiation oncology society in the world, ” said Jerry Lucas, MD, radiation oncologist, Arizona Oncology. “Evaluating our processes in relation to ASTRO’s high standards, including standards for safety and quality, validates our practices and recognizes the efforts of our radiation oncology team to deliver patient-centered radiation oncology care.” Accreditation through APEx is a rigorous, voluntary, multi-step process that can take up to one year to complete. Each center seeking APEx accreditation must have its policies and procedures evaluated using objective, verifiable expectations for performance in radiation oncology. It must demonstrate its commitment to high standards of safety and quality in the practice of radiation oncology and that it practices patient-centered care by promoting effective communication, coordinating treatment, and engaging patients and their families as partners in care. APEx has a distinctive program structure that includes both a self-assessment process and a facility visit conducted by a medical physicist and a radiation oncologist, radiation therapist, nurse, dosimetrist, nurse practitioner, physician assistant or practice administrator. APEx integrates Maintenance of Certification (MOC) templates that promote value and efficiency for physicians and final evaluation reports that link standards and performance to quality improvement resources. APEx applicants also have access to a library of quality improvement practice management tools to facilitate a culture of safety. APEx reflects competencies and practices identified and endorsed in the 2012 ASTRO publication Safety is No Accident: A Framework for Quality Radiation Oncology and Care. “ASTRO is proud to recognize Arizona Oncology for achieving APEx accreditation,” said ASTRO Chair David C. Beyer, MD, FASTRO. “Arizona Oncology has demonstrated a commitment to providing their patients with safe, high-quality radiation therapy services.” Arizona Oncology is one of the largest medical groups in Arizona. With more than 75 practicing physicians devoted exclusively to providing comprehensive, compassionate and high-quality cancer care, Arizona Oncology specializes in Medical, Gynecologic and Radiation Oncology, Hematology, Stem Cell Transplant, Research, Genetic Risk Assessment and patient ancillary programs. The physicians and their staff treat patients in many communities throughout the state including: Deer Valley, East Valley (Tempe), Estrella, Flagstaff, Glendale, Green Valley, Nogales, Peoria, Phoenix, Prescott Valley, Safford, Scottsdale, Sedona, and Tucson. Arizona Oncology believes it is beneficial to provide cancer therapies in a community setting, close to patients' homes and support systems. The physicians are supported by a talented clinical team sensitive to the needs of cancer patients and their caregivers. For more information, visit ArizonaOncology.com. Arizona Oncology is an affiliate of The US Oncology Network (“The Network”). This collaboration unites Arizona Oncology with more than 1,400 independent physicians dedicated to delivering value-based, integrated care for patients — close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The US Oncology Network is supported by McKesson Specialty Health, whose coordinated resources and infrastructure allow doctors in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices. Arizona Oncology also participates in clinical trials through US Oncology Research, which has played a role in nearly 70 FDA-approved cancer therapies, approximately one-third of all cancer therapies approved by the FDA to date. For more information, visit www.usoncology.com. ASTRO is the premier radiation oncology society in the world, with more than 10,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals who specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, the Society is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, advancement of science and research, and advocacy. ASTRO publishes three medical journals, International Journal of Radiation Oncology • Biology • Physics (www.redjournal.org), Practical Radiation Oncology (www.practicalradonc.org) and Advances in Radiation Oncology (www.advancesradonc.org); developed and maintains an extensive patient website, RT Answers (http://www.rtanswers.org); and created the Radiation Oncology Institute (www.roinstitute.org), a nonprofit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment. To learn more about ASTRO, visit www.astro.org.

Loading ASTRO collaborators
Loading ASTRO collaborators